Lithium recovery thermal management
US-2024336490-A1 · Oct 10, 2024 · US
US9453046B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9453046-B2 |
| Application number | US-201414774348-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 12, 2014 |
| Priority date | Mar 13, 2013 |
| Publication date | Sep 27, 2016 |
| Grant date | Sep 27, 2016 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Disclosed are methods of purifying mixtures comprising benzoidiazepine antibody-drug conjugates.
Opening claim text (preview).
What is claimed: 1. A method of removing benzodiazepine drug-related impurities from a mixture comprising benzodiazepine ADCs and benzodiazepine drug-related impurities comprising passing the mixture through an activated charcoal filter. 2. The method of claim 1 further comprising the steps of (i) contacting an antibody with a benzodizepine drug-linker under conditions sufficient to form a mixture comprising benzodiazepine ADCs, and (ii) contacting the mixture with a quenching agent to form quenched benzodiazepine drug-linkers. 3. The method of claim 1 further comprising the steps of (i) contacting an antibody conjugated to a linker with a benzodizepine drug under conditions sufficient to form a mixture comprising benzodiazepine ADCs and benzodiazepine drug-related impurities. 4. The method of claim 1 wherein the benzodiazepine drug-related impurities are quenched drug-linkers. 5. The method of claim 1 wherein the benzodiazepine drug-related impurities are unconjugated drugs. 6. The method of claim 1 wherein the activated charcoal is attached to a solid support. 7. The method of claim 1 wherein filtration is via single pass filtration or recirculation through a single filter. 8. The method of claim 1 wherein filtration is via multiple discrete filtrations through a single filter. 9. The method of claim 7 wherein filtration is via recirculation through a single filter when there is 10 g or less benzodiazepine ADC in the mixture and filtration is via single pass filtration when there is greater than 10 g benzodiazepine ADC in the mixture. 10. The method of claim 7 wherein there is greater than about 20 g benzodiazepine ADC in the mixture and filtration is via single pass filtration. 11. The method of claim 1 wherein the flux is between about 3 L/min/m 2 and 20 L/min/m 2 . 12. The method of claim 11 wherein the flux is between about 6 L/min/m 2 and 20 L/min/m 2 . 13. The method of claim 7 wherein filtration is via recirculation through a single filter and wherein the mixture comprising benzodiazepine ADCs and benzodiazepine drug-related impurities is recirculated from 3 to about 20 times through a single filter. 14. The method of claim 1 wherein the benzodiazepine drug-related impurities are reduced to a level of about 1 μM or less. 15. The method of claim 14 wherein the benzodiazepine drug-related impurities are reduced to a level of about 0.5 μM or less. 16. The method of claim 1 wherein the activated charcoal filter is an activated carbon cartridge or capsule. 17. The method of claim 1 wherein prior to activated charcoal filtration, the mixture is filtered via dead-end filtration or depth filtration. 18. The method of claim 1 wherein following activated charcoal filtration, the resultant mixture is subjected to one or more additional purification processes. 19. The method of claim 1 wherein the benzodiazepine ADCs comprise pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, or oxazolidinobenzodiazepine dimers. 20. The method of claim 1 wherein the antibody is conjugated to the benzodiazepine drug via a cysteine residue which is engineered into the antibody at position 239 of the IgG1 chain according to EU index numbering. 21. The method of claim 20 wherein there are an average of about 2 drug-linkers per antibody in the mixture.
Selective adsorption, e.g. chromatography · CPC title
Hinge · CPC title
against the immunoglobulin superfamily · CPC title
Ortho-condensed systems · CPC title
Complete heavy chain or Fd fragment, i.e. VH + CH1 · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.